Wells Fargo raises Carter’s stock price target on improved strategy By Investing.com

Wells Fargo raised Carter’s price target to $33 from $28 but kept an Underweight rating, citing improved first-quarter expectations alongside a weaker second-quarter outlook and no expected full-year guidance boost. Carter’s is on track for four straight quarters of positive comparable sales, but tariff pressure is still preventing margin improvement despite better demand creation and reduced discounting. The stock trades at $37.57, above Wells Fargo’s target, after a 21% gain over the past six months.

Analysis

The market is starting to price a “good enough” turnaround in CRI, but the key issue is not near-term beats — it is whether the new operating model can expand gross margin without a clean tariff unwind. The second-order risk is that management’s pivot toward full-price selling and brand collaborations improves sell-through but also raises execution complexity and working capital needs, which can cap incremental free cash flow even if comps stay positive.

The main near-term catalyst is guidance commentary, not the print itself. If the company avoids a full-year raise despite another quarter of positive comps, the stock’s recent momentum looks vulnerable because the multiple has already re-rated ahead of fundamental proof. In that setup, the path of least resistance is a “sell the news” reaction over the next 1-4 weeks, especially given the current price sits above the revised target set by one large broker and close to the upper end of street estimates.

The contrarian read is that the bullish case is now being underwritten by investor sentiment more than earnings power. What the market may be missing is that a product/marketing-led recovery tends to show up first in revenue and only later in margin, so the next 2-3 quarters could feature improving top-line optics but disappointing operating leverage if tariff pressure persists. That creates a fragile setup: any evidence that discounting creeps back or inventory tightens would likely unwind the multiple quickly, while a clean margin inflection would force a sharp rethink of the bear case.

For the broader analyst ecosystem, the upgrade/downgrade cluster around the name signals that consensus is converging on “improving but not yet fixed,” which usually compresses upside rather than expands it. This is the kind of stock where good news is increasingly pre-owned, and the burden of proof shifts to Q2 and back-to-school demand rather than the upcoming quarter alone.

Key Decisions for Investors

• Short CRI into earnings or on any post-print gap-up: risk/reward favors a 1-2 month fade if guidance stays unchanged and margin commentary remains tariff-constrained; cover only if management raises FY outlook or gross margin expands materially.
• Pair trade: long WFC/GS vs short CRI over the next 4-8 weeks if you want to express the analyst-call premium over the operating reality; the brokers benefit from recurring event-flow, while CRI needs multiple quarters of proof.
• If holding CRI long, use upside calls rather than equity into the report: buy near-dated call spreads for a tactical beat, but cap risk because the setup is more likely to be guided than structurally re-rated.
• Set a trailing stop on any CRI long position around the post-earnings reaction low; the stock has already absorbed a meaningful sentiment rerating, so downside can accelerate if comps are good but margins fail to follow.
• Watch for a better entry only after Q2: if management proves margin expansion after the tariff drag, then a 3-6 month re-rating becomes more credible; before that, the asymmetry still looks skewed toward disappointment.